Purines and Pyrimidine Metabolism I - Comprehensive Notes

Overview

• Purines vs pyrimidines basics
  • Purines: bases include Guanine, Adenine; pyrimidines: Guanine, Cytosine, Uracil, Thymine. Nucleotide synthesis occurs through regulated pathways.
  • Purine synthesis is a ten-step process; pyrimidine synthesis is described as five phases in the provided slides. Intermediates in purine pathways can be toxic, so tight regulation is essential.
• Purine nucleotides serve as building blocks for essential biomolecules and cofactors:
  • Electron carriers: FAD, NAD+, NADP+.
  • Coenzyme A (CoA) for TCA, lipid synthesis/oxidation.
  • cAMP as a second messenger (e.g., PKA activation).
• Key through-lines:
  • PRPP is the activated sugar backbone for both salvage and de novo purine synthesis.
  • IMP is the central purine precursor (an intermediate) that branches to AMP and GMP.
  • N10-formyl tetrahydrofolate (N10-formyl-THF) donates one-carbon units in purine assembly.
  • Purine biosynthesis is energy-intensive and highly regulated, with feedforward and feedback controls.

Learning objectives (brief alignment)

• Describe PRPP biosynthesis from ribose-5-phosphate (R5P) and ATP via PRPP synthetase.
• Describe the multistep process to form inosine monophosphate (IMP).
• Describe how IMP is converted to AMP and GMP.
• Describe how N10-formyl-THF is produced from folate.
• Describe origins of purine molecular subunits.
• Describe how PRPP acts as a feedforward activator while IMP, AMP, GMP provide feedback inhibition.

1. Biosynthesis of phosphoribosyl pyrophosphate (PRPP)

• Two nucleotide-building pathways exist:
  • Salvage pathway: use preformed nitrogenous bases from the diet/metabolism as building blocks for nucleotides (energy-saving).
  • De novo pathway: build nucleotides from simple molecules (energy-intensive).
• PRPP is the main precursor for all nucleotide synthesis in both purine and pyrimidine biosynthesis.
• Starting material: Ribose-5-phosphate (R5P)
  • R5P is an intermediate of the pentose phosphate pathway and glycolysis.
• PRPP synthesis reaction (PRPP synthetase):
  • Mechanism: ATP provides the two phosphates (pyrophosphate) to convert R5P to PRPP.
  • Reaction (simplified):
    $\text{R5P} + \text{ATP} \rightarrow \text{PRPP} + \text{AMP} + \text{PP}_i$
  • Cofactor: Mg^{2+}.
• Allosteric regulation of PRPP synthetase:
  • Activated by inorganic phosphate (Pi) and Mg^{2+} as cofactors.
  • Inhibited by ADP and GDP during low-energy states (feedback inhibition).
• PRPP usage:
  • Used in BOTH purine and pyrimidine synthesis via salvage and de novo pathways.
  • PRPP levels influence whether salvage or de novo pathways are activated.

2. The multistep process used to produce inosine monophosphate (IMP)

• Conceptual framework:
  • The purine ring is assembled stepwise directly on the ribose moiety; the process often occurs in multisubunit enzyme complexes (metabolons).
  • The final common intermediate for purine synthesis is IMP (inosine monophosphate).
  • Purine vs pyrimidine synthesis differ in organization; purine synthesis builds the ring on ribose; pyrimidine synthesis forms a separate ring that later attaches to ribose phosphate.
• Key context:
  • The liver is the primary organ for de novo nucleic acid synthesis and ammonia management (ammonia is a key component of purine biosynthesis).
• De novo purine synthesis substrates (for IMP):
  • Glutamine (Gln), aspartate (Asp), glycine (Gly), CO₂, and formate.
  • Initial committed step:PRPP amidotransferase transfers an amino group from Gln to PRPP to form 5-phosphoribosyl-1-amine (phosphoribosylamine).
  • Overall, there are 11 steps from PRPP to IMP (as noted in the lecture materials).
• First committed step (detailed):
  • PRPP amidotransferase catalyzes the transfer of an amino group from glutamine to PRPP, generating phosphoribosylamine and glutamate (with release of PPi).
  • Reaction (conceptual):
    $\text{PRPP} + \text{Gln} \rightarrow \text{phosphoribosylamine} + \text{glutamate} + \text{PP}_i$
• Regulation of PRPP amidotransferase (key control point):
  • Allosterically controlled and is activated initially by PRPP (feedforward activation).
  • Inhibited by end products: IMP, AMP, GMP (feedback inhibition).
  • Pi and Mg^{2+} serve as cofactors for the enzyme activity.
  • 6-Mercaptopurine (6-MP) is a chemotherapeutic inhibitor of PRPP amidotransferase, thereby reducing purine synthesis and DNA replication.
• Formylation steps (N10-formyl-THF donors):
  • Purine synthesis requires two one-carbon transfers from N10-formyl-THF to the growing purine ring.
  • These steps occur during the conversion from GAR (glycinamide ribotide) toward IMP (the exact intermediates are GAR → FGAR → FGAM → AIR → IMP, with THF-derived formyl groups contributing at key steps).
  • Two THF-dependent formyl transfers are crucial in forming the purine skeleton on ribose.
• Channeling concept (metabolic organization):
  • Enzymes in purine biosynthesis can assemble into multienzyme complexes, forming a channel to shuttle substrates/products and protect unstable intermediates from diffusion/degradation.
  • This channeling increases biosynthetic efficiency and minimizes loss of intermediates.
• Schematic of purine assembly (conceptual):
  • PRPP + Gly, Asp, Gln with THF-derived one-carbon units → progressively form GAR and subsequent intermediates → IMP.
• Nutritional and cofactor inputs:
  • Purine ring assembly machinery requires Gly, Asp, Gln as amino group donors and carbon donors from THF; ATP provides energy for early steps.

3. IMP usage: production of AMP and GMP

• IMP is the branch point that can lead to either AMP or GMP.
• AMP synthesis (adenylosuccinate pathway):
  • Energy requirement: GTP is used as an energy source and positive effector for the first AMP-forming step.
  • Step: IMP + GTP + Aspartate → adenylosuccinate; adenylosuccinate is converted to AMP + fumarate by adenylosuccinate lyase/synthase.
  • Regulation: AMP exerts feedback inhibition on the pathway (specifically on adenylosuccinate synthetase).
• GMP synthesis (guanosine monophosphate):
  • Step 1: IMP is oxidized to XMP by IMP dehydrogenase, with NAD^+ as the electron acceptor (NAD^+ + IMP → NADH + XMP).
  • Step 2: XMP amidotransferase (glutamine amidotransferase) uses ATP and glutamine to convert XMP to GMP, releasing ADP and PPi and producing glutamate.
  • Regulation: GMP inhibits IMP dehydrogenase (negative feedback).
• Balance and coordination:
  • The purine pathways maintain a balance between AMP and GMP levels; high levels of one nucleotide exert feedback to limit formation of more of that nucleotide.
  • Reciprocal regulation via energetic nucleotides:
  • GTP stimulates adenylosuccinate synthase (AMP formation pathway).
  • ATP stimulates XMP-glutamine amidotransferase (GMP formation pathway).
• General energy note:
  • Both AMP and GMP formation require energy inputs (GTP for AMP; ATP for GMP) to drive the reactions forward, especially when cellular energy is limiting.

4. N10-formyl tetrahydrofolate (N10-formyl-THF) and folate metabolism

• Folate (Vitamin B9) fundamentals:
  • Folate is an essential water-soluble vitamin absorbed in the duodenum.
  • Humans cannot synthesize folate; microorganisms synthesize folate de novo.
  • Folate storage in humans can last from about 3 weeks to 6 months; sources include leafy greens, nuts, and meats.
• Folate metabolism and THF:
  • Folate is converted to dihydrofolate (DHF) by dihydrofolate reductase (DHFR), and DHFR also reduces DHF to tetrahydrofolate (THF).
  • Trimethoprim inhibits bacterial DHFR (selectively affecting bacteria more than human DHFR by several thousand-fold affinity differences).
• Role of THF in purine synthesis:
  • THF and its one-carbon derivatives donate one-carbon units during purine biosynthesis, specifically via N10-formyl-THF (and other THF derivatives).
  • The C1 unit fate in THF has several possible roles:
  1. Direct use as N5-N10-methylene-THF in dUMP → dTMP via thymidylate synthase (this is a dTMP synthesis pathway, not a direct purine pathway).
  2. Reduction to N5-methyl-THF for methionine synthesis from homocysteine.
  3. Oxidation to N5-N10-methenyl-THF and back to N10-formyl-THF to participate in purine synthesis via two formyl transfers (as described above).
• N10-formyl-THF synthesis for purine biosynthesis:
  • Purine assembly requires two formyl transfers from N10-formyl-THF to the growing purine ring (noted in the GAR→FGAR and subsequent steps).
• Folate lifecycle and antibiotics:
  • Humans depend on dietary folate; bacteria synthesize folate, and DHFR is a target of antibiotics such as trimethoprim.

5. Origins of the purine molecule parts

• N9 position origin:
  • The N9 atom of the purine ring is already present from the initial glutamine-derived amino group during the early steps of purine synthesis.
• Nitrogen sourcing and energetic cost:
  • All purine nitrogen atoms are ultimately derived from amino acids (notably glutamine, aspartate, and glycine).
  • IMP biosynthesis is energetically expensive, involving the hydrolysis of roughly six ATP equivalents across the pathway.
• Overall framework:
  • The purine ring is assembled stepwise on the ribose, with nitrogen atoms supplied by amino acids and carbon units supplied by one-carbon donors (folate-derived THF). The process is highly energy-consuming and tightly regulated to balance cellular nucleotide pools.

6. Regulation of purine synthesis (PRPP and downstream nodes)

• PRPP synthesis and regulation:
  • The purine pathway starts with PRPP; salvage and de novo pathways both rely on PRPP.
  • PRPP synthetase activity is modulated by metabolic signals: activators include PPi (inorganic pyrophosphate) and 2,3-bisphosphoglycerate (2,3-BPG); inhibitors include ADP and GDP.
  • Regulation coordinates the total purine pool and the ATP/GTP balance (coordination of IMP, ATP, and GTP production).
• Key regulatory stages (IMP, AMP, GMP): 1) First committed step and PRPP amidotransferase control:
  • Gln-PRPP amidotransferase is feedback-inhibited by AMP, GMP, and IMP.
  • PRPP synthetase is also inhibited by the same factors, coordinating PRPP availability with end-product levels.
    2) Branch point from IMP (AMP and GMP branches):
  • AMP inhibits adenylosuccinate synthase (the step toward AMP).
  • GMP inhibits IMP dehydrogenase (the step toward GMP).
    3) Reciprocal regulation via GTP and ATP:
  • GTP stimulates adenylosuccinate synthase (AMP formation pathway).
  • ATP stimulates XMP-glutamine amidotransferase (GMP formation pathway).
• Nucleotide interconversion and energy currency:
  • Monophosphates are phosphorylated to diphosphates by specific kinases (Adenylate kinase for AMP, Guanylate kinase for GMP).
  • Diphosphates are further phosphorylated to triphosphates by nucleoside diphosphokinase (NDPK) for all nucleoside diphosphates.
  • Reactions involved:
    $\text{AMP} \leftrightarrow \text{ADP} \quad (adenylate\; kinase)$
    $\text{GMP} \leftrightarrow \text{GDP} \quad (guanylate\; kinase)$
    $\text{NDP} + \text{ATP} \rightarrow \text{NTP} + \text{ADP} \quad (NDPK)$
• Summary of regulatory architecture:
  • Three main regulatory axes: (i) committed step control via amidotransferase/PRPP; (ii) branch-point feedback (AMP on AMP pathway, GMP on GMP pathway); (iii) reciprocal control by ATP and GTP to direct flux toward the desired nucleotide pools.

7. Summary of de novo purine synthesis (key takeaways)

• PRPP is the essential sugar donor and is produced from R5P via PRPP synthetase (requires Mg^{2+} and ATP).
• Purine de novo synthesis proceeds via an integrated, enzyme-organized pathway that builds the purine ring on the ribose with amino donors (Gln, Asp, Gly) and one-carbon donors (N10-formyl-THF).
• IMP sits at the branch point for AMP and GMP formation, each requiring distinct energy inputs (GTP for AMP; ATP for GMP) and subject to feedback inhibition by the nucleotides themselves.
• N10-formyl-THF supplies two one-carbon units during purine assembly; folate metabolism is tightly linked to purine synthesis and is a drug target (e.g., trimethoprim inhibits bacterial DHFR).
• The early committed step (PRPP amidotransferase) is highly regulated by end-product feedback (AMP, GMP, IMP) and PRPP levels; inhibitors like 6-mercaptopurine demonstrate clinical relevance.
• Purine biosynthesis uses channeling within metabolons to enhance efficiency and protect labile intermediates.

8. Connections and broader context

• Connections to metabolism:
  • PRPP links purine/nucleotide biosynthesis to the pentose phosphate pathway and glycolysis through R5P supply.
  • Energy state of the cell (ATP, GTP, ADP, GDP) directly tunes the flux through AMP vs GMP branches.
• Real-world relevance:
  • Drugs targeting purine biosynthesis (e.g., 6-mercaptopurine, methotrexate via folate pathways) impact DNA synthesis and cell proliferation, useful in cancer therapeutics and immunosuppression.
• Ethical/philosophical/practical implications:
  • Antimetabolites illustrate the balance between cellular growth and resource allocation; precision in targeting microbial vs human enzymes minimizes host toxicity.

Formulas and key reactions (summary)

• PRPP synthesis from R5P:
  $\text{R5P} + \text{ATP} \rightarrow \text{PRPP} + \text{AMP} + \text{PP}_i$
• PRPP amidotransferase first committed step:
  $\text{PRPP} + \text{Gln} \rightarrow \text{phosphoribosylamine} + \text{glutamate} + \text{PP}_i$
• IMP to AMP (via adenylosuccinate):
  $\text{IMP} + \text{GTP} + \text{Asp} \rightarrow \text{adenylosuccinate} + \text{GDP} + \text{Pi}$
  $\text{adenylosuccinate} \rightarrow \text{AMP} + \text{fumarate}$
• IMP to GMP (oxidation and amidotransfer):
  $\text{IMP} + \text{NAD}^+ \rightarrow \text{XMP} + \text{NADH} + \text{H}^+$
  $\text{XMP} + \text{Gln} + \text{ATP} \rightarrow \text{GMP} + \text{ADP} + \text{PP}_i + \text{glutamate}$
• NDPK interconversion (general):
  $\text{NDP} + \text{ATP} \rightarrow \text{NTP} + \text{ADP}$
• Two THF one-carbon transfers in purine assembly (conceptual):
  $\text{GAR} + \text{N}^{10}\text{-formyl-THF} \rightarrow \text{FGAR} + \text{THF}$
  $\text{FGAR} + \text{N}^{10}\text{-formyl-THF} \rightarrow \text{AIR} + \text{THF}$